Voyager Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-119.72	-65	132.33	-46.41	-71.2	Upgrade
Depreciation & Amortization	4.06	4.73	4.44	6.19	5.17	Upgrade
Loss (Gain) From Sale of Assets	0.14	0.51	0.18	0.38	-	Upgrade
Asset Writedown & Restructuring Costs	-	2.78	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-2.97	-7.97	-3.63	-0.02	0.35	Upgrade
Stock-Based Compensation	14.79	14.79	11.15	9.34	11.32	Upgrade
Other Operating Activities	4.87	-	-	-2.47	-2.46	Upgrade
Change in Accounts Receivable	0.27	81.31	-83.23	0.48	7.28	Upgrade
Change in Accounts Payable	1.02	2.39	-0.96	1.99	-0.06	Upgrade
Change in Unearned Revenue	-28.81	-44.84	9.41	23.73	-1.72	Upgrade
Change in Other Net Operating Assets	-6.11	-4	8.23	-5.73	-2.21	Upgrade
Operating Cash Flow	-132.47	-15.31	77.92	-12.51	-53.53	Upgrade
Capital Expenditures	-2.6	-3.52	-3.26	-2.49	-1.61	Upgrade
Investment in Securities	128.04	-91.34	-138.39	-4.85	67.52	Upgrade
Investing Cash Flow	125.45	-94.86	-141.64	-7.34	65.91	Upgrade
Issuance of Common Stock	0.82	114.02	33.65	1.11	0.61	Upgrade
Financing Cash Flow	0.82	114.02	33.65	1.11	0.61	Upgrade
Net Cash Flow	-6.21	3.85	-30.08	-18.74	12.99	Upgrade
Free Cash Flow	-135.06	-18.83	74.66	-15	-55.13	Upgrade
Free Cash Flow Margin	-334.53%	-23.54%	29.86%	-36.67%	-147.36%	Upgrade
Free Cash Flow Per Share	-2.30	-0.33	1.68	-0.39	-1.46	Upgrade
Levered Free Cash Flow	-100.91	25.61	-3.01	7.25	3.94	Upgrade
Unlevered Free Cash Flow	-100.91	25.61	-3.01	7.25	4.18	Upgrade
Change in Working Capital	-33.63	34.86	-66.56	20.47	3.29	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.